Literature DB >> 20553919

Insulin-resistance and benign prostatic hyperplasia: the connection.

Ajit Vikram1, Gopabandhu Jena, Poduri Ramarao.   

Abstract

Benign prostatic hyperplasia (BPH) is a highly prevalent disease in the aged men population characterized by augmented cell proliferation and contractility of the prostate gland. Prior studies have demonstrated the relationship between BPH and insulin-resistance syndrome. During insulin-resistance, hyperinsulinemia develops to combat the decreased responsiveness of the body towards insulin. Although, the compensatory hyperinsulinemia prevents development of fasting hyperglycemia in insulin-resistant individuals, the increased level of circulating insulin directly and/or indirectly affects different molecular signaling and can promote prostatic growth. Insulin-resistance syndrome includes group of disorders, such as obesity, dyslipidemia, sympathetic overactivity, hyperinsulinemia and each individually reported as risk factor for the development of BPH. The present review describes the inter-relationships between different insulin-resistance associated factors and their possible involvement in the pathogenesis of BPH. Copyright (c) 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20553919     DOI: 10.1016/j.ejphar.2010.05.042

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  22 in total

1.  Pioglitazone attenuates prostatic enlargement in diet-induced insulin-resistant rats by altering lipid distribution and hyperinsulinaemia.

Authors:  Ajit Vikram; Gopabandhu Jena; Poduri Ramarao
Journal:  Br J Pharmacol       Date:  2010-12       Impact factor: 8.739

2.  Aging and Hyperglycemia Intensify Dyslipidemia-Induced Oxidative Stress and Inflammation in Rats: Assessment of Restorative Potentials of ALA and EPA + DHA.

Authors:  Pooja Acharya; Ramaprasad Ravichandra Talahalli
Journal:  Inflammation       Date:  2019-06       Impact factor: 4.092

Review 3.  Urological aspects of the metabolic syndrome.

Authors:  Jan Hammarsten; Ralph Peeker
Journal:  Nat Rev Urol       Date:  2011-08-02       Impact factor: 14.432

4.  Metabolic syndrome does not impair the response to alfuzosin treatment in men with lower urinary tract symptoms: a double-blind, randomized, placebo-controlled study.

Authors:  Selçuk Altın; Tunç Ozan; Selçuk İlhan; Nevin İlhan; Rahmi Onur
Journal:  Turk J Urol       Date:  2015-09

5.  Toll-like receptor 9 regulates metabolic profile and contributes to obesity-induced benign prostatic hyperplasia in mice.

Authors:  Fabiano B Calmasini; Cameron G McCarthy; Camilla F Wenceslau; Fernanda B M Priviero; Edson Antunes; R Clinton Webb
Journal:  Pharmacol Rep       Date:  2020-01-08       Impact factor: 3.024

Review 6.  PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia.

Authors:  Ming Jiang; Douglas W Strand; Omar E Franco; Peter E Clark; Simon W Hayward
Journal:  Differentiation       Date:  2011-06-08       Impact factor: 3.880

7.  Effect of obesity and hyperglycemia on benign prostatic hyperplasia in elderly patients with newly diagnosed type 2 diabetes.

Authors:  Zhe Chen; Li Miao; Xia Gao; Guang Wang; Yuan Xu
Journal:  Int J Clin Exp Med       Date:  2015-07-15

Review 8.  A review of the anticancer potential of the antimalarial herbal cryptolepis sanguinolenta and its major alkaloid cryptolepine.

Authors:  C Ansah; K B Mensah
Journal:  Ghana Med J       Date:  2013-09

9.  Are blood vessels a target to treat lower urinary tract dysfunction?

Authors:  Martin C Michel; Russ Chess-Williams; Sharath S Hegde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-05-31       Impact factor: 3.000

10.  Fraction of macroporous resin from Smilax china L. inhibits testosterone propionate-induced prostatic hyperplasia in castrated rats.

Authors:  Jing Chen; Chao-Mei Xiong; Shan-Shan Song; Pan Han; Jin-Lan Ruan
Journal:  J Med Food       Date:  2012-04-17       Impact factor: 2.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.